NasdaqGS:NBIXBiotechs
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug
In late January 2026, Neurocrine Biosciences began a Phase 2 randomized, double-blind, placebo-controlled trial of its investigational VMAT2 inhibitor NBI-1065890 in about 100 adults with tardive dyskinesia, measuring changes in Abnormal Involuntary Movement Scale scores over eight weeks.
This move extends Neurocrine’s two decades of VMAT2 research and existing FDA-approved valbenazine franchise, aiming to explore potentially longer-acting treatment options for movement disorders.
We’ll now...